GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poolbeg Pharma PLC (OTCPK:POLBF) » Definitions » Change In Inventory

POLBF (Poolbeg Pharma) Change In Inventory : $0.00 Mil (TTM As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Poolbeg Pharma Change In Inventory?

Poolbeg Pharma's change in inventory for the quarter that ended in Jun. 2024 was $0.00 Mil. It means Poolbeg Pharma's inventory stayed the same from Dec. 2023 to Jun. 2024 .

Poolbeg Pharma's change in inventory for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Poolbeg Pharma's inventory stayed the same from Dec. 2022 to Dec. 2023 .

Poolbeg Pharma's Total Inventories for the quarter that ended in Jun. 2024 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.


Poolbeg Pharma Change In Inventory Historical Data

The historical data trend for Poolbeg Pharma's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Poolbeg Pharma Change In Inventory Chart

Poolbeg Pharma Annual Data
Trend Dec21 Dec22 Dec23
Change In Inventory
- - -

Poolbeg Pharma Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Change In Inventory Get a 7-Day Free Trial - - - - -

Poolbeg Pharma Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Poolbeg Pharma  (OTCPK:POLBF) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Poolbeg Pharma's Days Inventory for the quarter that ended in is calculated as:

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Poolbeg Pharma's Inventory Turnover for the quarter that ended in Jun. 2024 is calculated as

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Poolbeg Pharma's Inventory to Revenue for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Poolbeg Pharma Change In Inventory Related Terms

Thank you for viewing the detailed overview of Poolbeg Pharma's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.


Poolbeg Pharma Business Description

Traded in Other Exchanges
Address
42 New Road, Queen Mary BioEnterprises Innovation Centre, London, GBR, E1 2AX
Poolbeg Pharma PLC is a clinical-stage infectious disease pharmaceutical company, with a novel capital-light clinical model which enables to develop of multiple products faster and more cost-effectively than the traditional biotech model. The company aspires to become a one-stop shop for pharma-seeking mid-stage products to license or acquire.